Impact of ERBB2 Mutations on in Vitro Sensitivity of Bladder Cancer to Lapatinib

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2014 Jun 28

PMID 24971884

Citations 20

Authors

Michela de Martino

Dazhong Zhuang

Tobias Klatte

Malte Rieken

Morgan Roupret

Evanguelos Xylinas

Thomas Clozel

Martin Krzywinski

Olivier Elemento

Shahrokh F Shariat

Affiliations

Soon will be listed here.

Abstract

Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC). We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of UBC and that these mutations impact ErbB2 function, signaling, UBC proliferation, gene expression, and predict response to lapatinib. We found ERBB2 mutations in 5 of 33 UBC cell lines (15%), all of which were derived from invasive or high grade tumors. Phosphorylation and activation of ErbB2 and its downstream pathways were markedly enhanced in mutated cell lines compared with the ERBB2 wild-type. In addition, the gene expression profile was distinct, specifically for genes encoding for proteins of the extracellular matrix. RT112 cells infected with ERBB2 mutants showed a particular growth pattern ("mini-foci"). Upon treatment with lapatinib, 93% of these "mini-foci" were reversed. The sensitivity to lapatinib was greatest among cell lines with ERBB2 mutations. In conclusion, ERBB2 mutations occur in a subset of UBC and impact proliferation, signaling, gene expression and predict a greater response to lapatinib. If confirmed in the clinical setting, this may lead the way toward personalized treatment of a subset of UBC.

Citing Articles

DeepKEGG: a multi-omics data integration framework with biological insights for cancer recurrence prediction and biomarker discovery.

Lan W, Liao H, Chen Q, Zhu L, Pan Y, Chen Y Brief Bioinform. 2024; 25(3).

PMID: 38678587 PMC: 11056029. DOI: 10.1093/bib/bbae185.

Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.

Leary J, Enright T, Bakaloudi D, Basnet A, Bratslavsky G, Jacob J Target Oncol. 2024; 19(3):447-458.

PMID: 38570422 DOI: 10.1007/s11523-024-01056-x.

Molecular profile of bladder cancer progression to clinically aggressive subtypes.

Guo C, Lee S, Lee J, Chen H, Zaleski M, Choi W Nat Rev Urol. 2024; 21(7):391-405.

PMID: 38321289 DOI: 10.1038/s41585-023-00847-7.

Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma.

Qu M, Zhou L, Yan X, Li S, Wu X, Xu H Bladder (San Franc). 2023; 10:e21200012.

PMID: 38155921 PMC: 10752798. DOI: 10.14440/bladder.2023.871.

Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer.

Devis-Jauregui L, Vidal A, Plata-Pena L, Santacana M, Garcia-Mulero S, Bonifaci N Adv Sci (Weinh). 2022; :e2204211.

PMID: 36373729 PMC: 9811454. DOI: 10.1002/advs.202204211.

References

Fleishman S, Schlessinger J, Ben-Tal N . A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002; 99(25):15937-40. PMC: 138543. DOI: 10.1073/pnas.252640799. View

Guo Y, Chekaluk Y, Zhang J, Du J, Gray N, Wu C . TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol. 2013; 230(1):17-27. DOI: 10.1002/path.4176. View

de Hoon M, Imoto S, Nolan J, Miyano S . Open source clustering software. Bioinformatics. 2004; 20(9):1453-4. DOI: 10.1093/bioinformatics/bth078. View

Bose R, Kavuri S, Searleman A, Shen W, Shen D, Koboldt D . Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2012; 3(2):224-37. PMC: 3570596. DOI: 10.1158/2159-8290.CD-12-0349. View

Gunes S, Sullu Y, Yegin Z, Buyukalpelli R, Tomak L, Bagci H . ErbB receptor tyrosine kinase family expression levels in urothelial bladder carcinoma. Pathol Res Pract. 2013; 209(2):99-104. DOI: 10.1016/j.prp.2012.10.014. View

Rink M, Chun F, Dahlem R, Soave A, Minner S, Hansen J . Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012; 61(4):810-7. DOI: 10.1016/j.eururo.2012.01.017. View

Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C . Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010; 28(4):401-8. DOI: 10.1016/j.urolonc.2009.04.019. View

Bellmunt J, Hussain M, Dinney C . Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003; 46 Suppl:S85-104. DOI: 10.1016/s1040-8428(03)00067-2. View

Bolenz C, Shariat S, Karakiewicz P, Ashfaq R, Ho R, Sagalowsky A . Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010; 106(8):1216-22. DOI: 10.1111/j.1464-410X.2009.09190.x. View

10.

Halterman P . Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Pharmacotherapy. 2008; 28(10):1255-66. DOI: 10.1592/phco.28.10.1255. View

11.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

12.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

13.

de Hoon M, Imoto S, Miyano S . Statistical analysis of a small set of time-ordered gene expression data using linear splines. Bioinformatics. 2002; 18(11):1477-85. DOI: 10.1093/bioinformatics/18.11.1477. View

14.

Garrett J, Arteaga C . Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011; 11(9):793-800. PMC: 3230295. DOI: 10.4161/cbt.11.9.15045. View

15.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

16.

McHugh L, Kriajevska M, Mellon J, Griffiths T . Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. Urology. 2007; 69(2):390-4. DOI: 10.1016/j.urology.2006.12.003. View

17.

Volpe A, Racioppi M, DAgostino D, DAddessi A, Marangi F, Totaro A . Advanced bladder cancer: new agents and new approaches. A review. Urol Oncol. 2010; 31(1):9-16. DOI: 10.1016/j.urolonc.2010.03.022. View

18.

Tsai Y, Yeh C, Tzen K, Ho P, Tuan T, Pu Y . Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer. 2012; 49(6):1458-66. DOI: 10.1016/j.ejca.2012.10.020. View

19.

Herter-Sprie G, Greulich H, Wong K . Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol. 2013; 3:86. PMC: 3632856. DOI: 10.3389/fonc.2013.00086. View

20.

Junttila T, Laato M, Vahlberg T, Soderstrom K, Visakorpi T, Isola J . Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res. 2003; 9(14):5346-57. View